Low‐Dose Bevacizumab in HCC: Unresolved Questions on Hepatic Reserve, Cost Claims, and LRT Heterogeneity

Key Points

• This analysis aims to explore unresolved questions regarding the use of low-dose bevacizumab in patients with HCC.
• Analyzed existing literature on low-dose bevacizumab and its effects in HCC.
• Considered factors like hepatic reserve and treatment costs.
• Identified inconsistencies in reported cost-efficiencies of low-dose bevacizumab.
• Noted variability in liver function's impact on treatment outcomes.